The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years due to Washington's insistence on sensitive information.
This rejection came to light after a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government representative has since explained that the US was seeking genetic material for research and commercial gain while was not willing to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further negotiations to find a deal agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the safety of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
According to reports, 16 nations in Africa have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Put simply, our country would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a future pandemic emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting structures previously established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how future collaboration might be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but urged that negotiations must proceed given that much of the nation's HIV programmes relied on external financing.
"If technical issues arise, including those relating to data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal emphasises the complex challenges between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.